Atrial fibrillation (AF) with RVR is defined as AF with a ventricular rate >100 bpm (often >120–150 bpm), caused by disorganized atrial electrical activity with uncoordinated atrial contraction and rapid, irregular conduction through the AV node. [1-2] The critical first step in management is determining hemodynamic stability and differentiating primary AF (AF is the problem) from secondary AF (AF driven by an underlying trigger such as sepsis, PE, or thyrotoxicosis). [3-4]
1. History
- Onset and duration: New-onset vs. recurrent paroxysmal AF; duration <48 hours vs. >48 hours (critical for cardioversion and anticoagulation decisions) [1][4]
- Symptom characterization: Palpitations (27–70%), dyspnea (28–76%), fatigue (26–75%), chest pain (12–30%), dizziness (19–44%), presyncope/syncope (3–4%) [5]
- Triggers: Alcohol/binge drinking, sleep deprivation, emotional stress, recent surgery, acute illness, stimulants, large meals [2][6]
- Prior episodes: Frequency, prior treatments, prior cardioversions, known AF subtype (paroxysmal, persistent, permanent)
- Medication compliance: Current rate-control agents, anticoagulation status and adherence
- Important negatives: Absence of chest pain, focal neurologic deficits, hemoptysis, fever, recent surgery
2. Alarm Features
- Hemodynamic instability: Hypotension (SBP <90), altered mental status, signs of shock → immediate synchronized cardioversion [1][7]
- Acute heart failure/pulmonary edema: Dyspnea, crackles, JVD, hypoxia [8]
- Acute coronary syndrome: Chest pain with ischemic ECG changes, elevated troponin [3]
- Stroke/TIA symptoms: Focal neurologic deficits, aphasia, facial droop
- Pre-excited AF (WPW): Wide-complex irregular tachycardia, rates >200 bpm → avoid AV nodal blockers; proceed to cardioversion or procainamide [1-2]
- Syncope or near-syncope [8]
3. Medications
Rate Control (first-line for hemodynamically stable patients): [1][9]
Contraindicated medications
- IV diltiazem/verapamil in moderate-severe LV systolic dysfunction (Class 3: Harm) [9]
- AV nodal blockers (diltiazem, verapamil, beta-blockers, IV amiodarone, digoxin) in pre-excited AF (WPW) — risk of VF [1]
Anticoagulation: DOACs are first-line for stroke prevention; warfarin reserved for mechanical valves or moderate-severe mitral stenosis [6][8]
4. Diet
- Alcohol: Dose-dependent AF risk factor; binge drinking is a well-established trigger ("holiday heart"); abstinence reduces recurrence [6][10]
- Caffeine: Has not been shown to increase AF incidence [8]
- Hydration: Assess volume status; dehydration may exacerbate tachycardia
- Long-term: Mediterranean diet pattern, weight loss ≥10% in obese patients associated with reduced AF burden [10]
5. Review of Systems
- Cardiovascular: Palpitations, chest pain, dyspnea on exertion, orthopnea, PND, lower extremity edema, syncope
- Pulmonary: Cough, hemoptysis, pleuritic chest pain (PE), snoring/witnessed apneas (OSA)
- Endocrine: Heat intolerance, weight loss, tremor (hyperthyroidism)
- Neurologic: Focal weakness, speech difficulty, vision changes (stroke/TIA)
- GI: Recent heavy alcohol use, vomiting/diarrhea (electrolyte derangements)
- Infectious: Fever, chills (sepsis as secondary trigger)
6. Collateral History and Family History
- Collateral: Medication compliance (especially anticoagulants), alcohol/substance use, witnessed seizure or syncope, baseline functional status
- Family history: AF has a heritable component; family history of AF, sudden cardiac death, cardiomyopathy, or WPW should be elicited [11-12]
- Social context: Substance use (stimulants, alcohol), occupational demands, ability to follow up
7. Risk Factors
Modifiable: [6][10-11]
Non-modifiable: [11]
Acute triggers for RVR: [3-4]
8. Differential Diagnosis
- Atrial flutter with variable block (sawtooth pattern, often regular or regularly irregular) [13]
- Multifocal atrial tachycardia (MAT): Irregularly irregular but with ≥3 distinct P-wave morphologies; associated with COPD, hypoxia [13]
- SVT with aberrant conduction: Regular narrow-complex tachycardia; AF with RVR at very fast rates can mimic regular SVT [14]
- Ventricular tachycardia: Wide-complex; rates >200 bpm with AF suggest accessory pathway or VT [2]
- Sinus tachycardia: Regular, gradual onset/offset, identifiable P waves; consider secondary causes (sepsis, PE, hypovolemia)
- Pre-excited AF (WPW): Irregular wide-complex tachycardia — cannot-miss diagnosis [1]
9. Past Medical History
- Prior AF episodes, cardioversions, ablations
- Heart failure (HFrEF vs. HFpEF — impacts drug selection) [9]
- Valvular heart disease (especially mitral stenosis — impacts anticoagulant choice)
- Prior stroke/TIA (impacts CHA₂DS₂-VASc and urgency of anticoagulation)
- Thyroid disease, OSA, COPD, CKD
- Surgical history (recent cardiac or thoracic surgery)
- Bleeding history (impacts anticoagulation decisions)
10. Physical Exam
- Vitals: Heart rate (typically >100, often 130–170), blood pressure (assess for hypotension), respiratory rate, SpO₂
- Cardiac: Irregularly irregular rhythm, variable S1 intensity, absence of S4, pulse deficit (apical rate > radial rate) [4][15]
- Jugular veins: Irregular venous pulsations, elevated JVP (HF), absent "a" waves
- Lungs: Crackles (pulmonary edema), wheezing (COPD/asthma — impacts beta-blocker use)
- Extremities: Peripheral edema, cool/mottled extremities (poor perfusion)
- Thyroid: Goiter, thyroid nodules, exophthalmos
- Neurologic: Focal deficits (stroke screening)
11. Lab Studies
Per the 2023 ACC/AHA/ACCP/HRS Guideline, recommended labs for newly diagnosed AF: [6][9]
- CBC: Anemia (exacerbates tachycardia), infection
- BMP/CMP: Electrolytes (K⁺, Mg²⁺, Ca²⁺), renal function (impacts drug dosing/anticoagulation), glucose
- TSH: Hyperthyroidism is a reversible cause [8-9]
- Hepatic function: Impacts anticoagulant selection
- Troponin: Reasonable if concern for ACS or to risk-stratify; not required in low-risk recurrent paroxysmal AF [3][9]
- BNP/NT-proBNP: If HF suspected
- Coagulation studies: If initiating anticoagulation or concern for bleeding
- Do NOT routinely order: D-dimer, CT-PE, or stress testing unless clinical suspicion warrants [9]
12. Imaging
- Transthoracic echocardiogram (TTE): Recommended for all new-onset AF — assesses LV/RV function, chamber size, valvular disease, LA size, pulmonary pressures [6][9]
- Chest X-ray: If pulmonary disease or HF suspected; may show cardiomegaly, pulmonary edema [15]
- TEE: Before cardioversion if AF duration >48 hours (or unknown) in non-anticoagulated patients — to rule out LA/LAA thrombus [4]
- CT chest: Only if PE clinically suspected
- Imaging for ischemia is not routinely indicated in the absence of signs/symptoms [9]
13. Special Tests
<runcalculator>CHA2DS2VAScCalculator</runcalculator>
- HAS-BLED Score: Assesses bleeding risk; high score should prompt risk factor modification, not necessarily withholding anticoagulation [16]
- Disposition scores: RED-AF, AFFORD, AFTER scores can assist with ED disposition decisions [3]
- Sleep study: Screen for OSA in all AF patients; treat if present [8]
14. ECG
Diagnostic findings: [2][8]
- Irregularly irregular R-R intervals (hallmark)
- Absence of discrete P waves — replaced by fibrillatory waves varying in amplitude, shape, and timing
- Variable baseline oscillation between QRS complexes
- Narrow QRS (<120 ms) unless pre-existing bundle branch block or accessory pathway
Dangerous patterns to recognize
- Wide-complex irregular tachycardia: Pre-excited AF (WPW) or AF with BBB — rates >200 bpm strongly suggest accessory pathway [2]
- Regular R-R intervals in AF: Suggests concurrent AV block or junctional/ventricular tachycardia [2]
- ST changes: May represent demand ischemia from tachycardia vs. ACS
- QT prolongation: Important before initiating antiarrhythmics
The following figure demonstrates a 12-lead ECG of AF with RVR, showing the characteristic irregularly irregular narrow-complex tachycardia with absent P waves:
15. Assessment
- Severity stratification: Hemodynamically stable vs. unstable is the primary branch point [1][7]
- Primary vs. secondary AF: If secondary, treat the underlying cause (sepsis, PE, thyrotoxicosis) — rate control alone may be insufficient if the trigger is not addressed [3]
- Tachycardia-mediated cardiomyopathy: Persistent rates >110 bpm can cause reversible LV dysfunction [8]
- Typical presentation: Middle-aged to elderly patient with palpitations, dyspnea, and irregularly irregular tachycardia
- Atypical presentations: Asymptomatic (10–40%), presenting with stroke, HF, or fatigue alone [6]
- Complications: Stroke/thromboembolism, heart failure, cardiogenic shock, cardiac ischemia
16. Treatment Plan
Hemodynamically unstable: [1][7]
- Immediate synchronized cardioversion (biphasic 120–200 J; increase energy if unsuccessful)
- Do not delay for anticoagulation status
Hemodynamically stable: [1][9]
- Rate control (initial target HR <110 bpm): [4]
- First-line: IV diltiazem or IV metoprolol (see dosing table above)
- If EF ≤40% or decompensated HF: IV amiodarone or IV digoxin [9]
- Adjunct: IV magnesium 2 g [9]
- Rhythm control (consider if <48 hours, highly symptomatic, or first episode): [4]
- Electrical cardioversion (92–96% success for recent-onset AF) [4]
- Pharmacologic: IV amiodarone, procainamide, or ibutilide
- If >48 hours and not anticoagulated: TEE to exclude thrombus before cardioversion, or anticoagulate ≥3 weeks prior [1][4]
- Anticoagulation: [6][8]
- Assess CHA₂DS₂-VASc score
- DOACs preferred (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin for non-valvular AF
- Initiation in the ED is safe [4]
- Post-cardioversion: Anticoagulate for minimum 4 weeks regardless of CHA₂DS₂-VASc [4]
- Risk factor modification: [6][10]
The following figure from JAMA illustrates the comprehensive AF treatment care pathway:
17. Disposition
Admit if: [3][6]
- Hemodynamic instability or requiring cardioversion
- Refractory to rate control despite adequate dosing
- New-onset AF with significant comorbidities (HF, ACS, stroke)
- Ongoing need for IV rate-control infusion
- Significant underlying trigger requiring inpatient management (sepsis, PE, thyroid storm)
- New-onset AF with reduced EF
Observation unit: [4]
- Rate-controlled AF awaiting echocardiography or further workup
- Elective cardioversion candidates
Discharge if: [3]
- Known paroxysmal AF with episode similar to prior events
- Rate controlled (HR <110) and symptomatically improved
- Hemodynamically stable with reliable follow-up
- Anticoagulation addressed and prescribed
- Oral rate-control medication tolerated
- Disposition tools (RED-AF, AFFORD, AFTER scores) can assist decision-making [3]
Specialist consultation triggers
- Cardiology/EP: New-onset AF, refractory rate control, rhythm control consideration, ablation candidacy
- Hematology: Complex anticoagulation scenarios
18. Follow Up / Return Precautions
- Follow-up timing: PCP or cardiology within 1–2 weeks for new-onset AF; sooner if newly started on anticoagulation
- Echocardiogram: If not obtained in ED, arrange outpatient TTE
- Return immediately for: Chest pain, severe dyspnea, syncope/near-syncope, focal weakness or speech difficulty, uncontrolled palpitations, signs of bleeding (on anticoagulation)
- Expected course: Many patients with new-onset AF will spontaneously convert; paroxysmal AF may recur [4]
- Patient counseling: Medication adherence (especially anticoagulation), alcohol avoidance, weight management, sleep apnea screening, when to seek emergency care
References
1. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Wigginton JG, Agarwal S, Bartos JA, et al. Circulation. 2025.
2. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Partnership With the European Society of Cardiology and in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. — Fuster V, Rydén LE, Cannom DS, et al. Journal of the American College of Cardiology. 2011.
3. Emergency Medicine Updates: Atrial Fibrillation With Rapid Ventricular Response. — Long B, Brady WJ, Gottlieb M. The American Journal of Emergency Medicine. 2023.
4. Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. — Chyou JY, Barkoudah E, Dukes JW, et al. Circulation. 2023.
5. State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association. — Jurgens CY, Lee CS, Aycock DM, et al. Circulation. 2022.
6. Atrial Fibrillation: A Review. — Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH. The Journal of the American Medical Association. 2025.
7. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Panchal AR, Bartos JA, Cabañas JG, et al. Circulation. 2020.
8. Atrial Fibrillation. — Michaud GF, Stevenson WG. The New England Journal of Medicine. 2021.
9. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Writing Committee Members, Joglar JA, Chung MK, et al. Journal of the American College of Cardiology. 2024.
10. Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification. — O'Keefe EL, Sturgess JE, O'Keefe JH, Gupta S, Lavie CJ. The American Journal of Cardiology. 2021.
11. Atrial Fibrillation: JACC Council Perspectives. — Chung MK, Refaat M, Shen WK, et al. Journal of the American College of Cardiology. 2020.
12. Precision Medicine Approaches to Cardiac Arrhythmias: JACC Focus Seminar 4/5. — Giudicessi JR, Ackerman MJ, Fatkin D, Kovacic JC. Journal of the American College of Cardiology. 2021.
13. Common Types of Supraventricular Tachycardia: Diagnosis and Management. — Nasir M, Sturts A, Sturts A. American Family Physician. 2023.
14. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Heart Rhythm. 2016.
15. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — January CT, Wann LS, Alpert JS, et al. Circulation. 2014.
16. Atrial Fibrillation: Common Questions and Answers About Diagnosis and Treatment. — Holder S, Amin P. American Family Physician. 2024.
17. Narrow QRS Complex Tachycardia. — Courtney B. Saunders, Jeffrey D. Ferguson The Electrocardiagram in Emergency and Acute Care. 2023.